High impactLayoffs

Cellectis Plans Up to 70% Workforce Cut Amid Gene Therapy Pivot

NewsData.io · United States · Nov 15, 2026

Cellectis, a biotech firm with operations in New York and Raleigh, NC, plans to reduce its global workforce by up to 70%—potentially 160 of its 229 employees—as it exits cell therapy and pivots to in vivo gene editing. The cuts are expected to roll out through 2026 and 2027, pending completion of French works council consultation and compliance with both French and U.S. labor law. The company has also halted enrollment in its CAR-T clinical programs. Recruiters supporting life sciences clients should note the emerging candidate supply in biotech, particularly in gene therapy and clinical operations roles, as this reduction is part of a broader wave of biotech layoffs trending upward year over year.

Get the weekly brief by email

What changed in staffing last week, every Monday morning. Free. Unsubscribe anytime.

Cellectisbiotechnologylife sciencesgene therapy

Related stories